Core Viewpoint - The announcement indicates a reduction in shareholding by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in the company, which does not affect the control structure or governance of the company [1] Group 1: Shareholding Changes - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. reduced its shareholding from 11,020,753 shares to 9,610,957 shares [1] - The percentage of total share capital held by Zhangjiang decreased from 7.82% to 6.82% [1] - The reduction involved a sale of 1,409,796 shares through a centralized bidding transaction, and the plan has been fully implemented [1] Group 2: Impact on Company Structure - The shareholding change does not trigger a mandatory tender offer [1] - There will be no change in the company's controlling shareholder or actual controller [1] - The governance structure and ongoing operations of the company will not be significantly impacted [1]

格隆汇1月8日丨益诺思(688710.SH)公布，公司于2026年1月8日收到张江生药基地出具的书面告知函。 截至2026年1月7日，张江生药基地通过集中竞价方式减持公司140.98万股股份，占公司总股本的 1.00%。 ...

Summary of Key Points Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. has completed a share reduction plan, selling 1.4098 million shares of Yinos, which represents 1.00% of the total share capital, at a price range of 43.55 to 55.31 yuan per share, totaling 66.9177 million yuan [1]. Group 1 - The share reduction occurred between December 22, 2025, and January 7, 2026 [1]. - After the reduction, the shareholder holds 9.611 million shares, which is 6.82% of the total shares, down from 11.0208 million shares, or 7.82% prior to the reduction [1]. - This change in equity ownership triggered a change that touches the 1% integer multiple, indicating a significant adjustment in the shareholder's stake [1].

Group 1 - The core point of the article highlights the stock performance of Yinos, which increased by 5.19% to reach a price of 58.18 CNY per share, with a trading volume of 181 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 8.202 billion CNY [1] - Yinos is a biotechnology company based in the China (Shanghai) Free Trade Zone, established on May 12, 2010, and listed on September 3, 2024. The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Among the top ten circulating shareholders of Yinos, a fund under Huatai-PineBridge is noted, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top ten shareholders in the third quarter with 1.1215 million shares, accounting for 1.24% of circulating shares. The estimated floating profit for today is approximately 3.2188 million CNY [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY. Year-to-date returns are 6.72%, ranking 749 out of 8825 in its category, while the one-year return is 36.03%, ranking 3440 out of 8084. Since its inception, the fund has achieved a return of 162.46% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a cumulative tenure of 11 years and 26 days. The total asset scale under his management is 8.093 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -35.19% [2]

Group 1 - The core viewpoint of the news is that Yinosh experienced a significant increase in stock price and trading volume, indicating strong investor interest and activity [1] - On January 7, Yinosh's stock rose by 20.00%, with a trading volume of 317 million yuan, and a net financing purchase of 50.92 million yuan [1] - As of January 7, the total margin balance for Yinosh was 111 million yuan, accounting for 2.21% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, Yinosh had 4,849 shareholders, a decrease of 9.97% from the previous period, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% [2] - Since its A-share listing, Yinosh has distributed a total of 45.11 million yuan in dividends [3]

证券之星消息，1月7日医疗服务板块较上一交易日上涨1.7%，益诺思领涨。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 55.31 | 20.00% | 5.97万 | | 3.17亿 | | 688222 | 成都先导 | 30.44 | 13.67% | 44.49万 | | 13.43亿 | | 301293 | 三博脑科 | 93.82 | 10.45% | 74.53万 | | 68.62亿 | | 002173 | 创新医疗 | 28.63 | 9.99% | 10.16万 | | 2.91亿 | | 688621 | 阳光诺和 | 72.10 | 7.77% | 6.88万 | | 4.95 乙 | | 603127 | 昭衍新药 | 41.30 | 7.41% | 36.68万 | | 14.97亿 | | ...

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

南方财经1月7日电，医疗研发外包板块走高，益诺思涨停，成都先导涨超10%，博济医药、药康生物、 昭衍新药、皓元医药、阳光诺和等跟涨。 ...

Group 1 - Core viewpoint: Yinos Biotech Co., Ltd. has seen a stock price increase of 5.66%, reaching 46.65 CNY per share, with a total market capitalization of 6.577 billion CNY as of January 5 [1] - Company overview: Yinos Biotech, established on May 12, 2010, is located in the China (Shanghai) Pilot Free Trade Zone and specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] - Revenue breakdown: The company's revenue composition includes 96.31% from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Major shareholder: Huatai-PineBridge Fund's Huatai Medical Health Mixed Fund (470006) has entered the top ten circulating shareholders of Yinos, holding 1.1215 million shares, which is 1.24% of the circulating shares [2] - Fund performance: The Huatai Medical Health Mixed Fund has achieved a year-to-date return of 22.9%, ranking 4015 out of 8155 in its category, with a total fund size of 2.486 billion CNY [2] - Fund manager: The fund manager, Zheng Lei, has been in position for 11 years and 23 days, overseeing a total asset size of 8.093 billion CNY, with the best fund return during his tenure being 53.42% [3]